A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
Study identifier:D5130L00019
ClinicalTrials.gov identifier:NCT01611272
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
Medical condition
Acute Coronary Syndromes
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
3402
Study type
Observational
Age
19 Years - 130 Years
Date
Study Start Date: 30 Apr 2013
Primary Completion Date: 20 Jul 2016
Study Completion Date: 20 Jul 2016
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verification:
Verified 01 Jul 2017 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| 1 Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting | - |
Contacts
Investigators
Principal Investigator
JooWon Lee
AstraZeneca Korea
